麻豆原创

Published on 麻豆原创 Research Reports庐 Inc. ()

麻豆原创 > Immune Checkpoint Therapeutics - Hot Targets & Pipeline Analysis

Immune Checkpoint Therapeutics - Hot Targets & Pipeline Analysis

Publication ID: 
IQ40416001
Publication Date: 
April 26, 2016
Pages: 
161
Publisher: 
IQ4I
Countries: 
Global [1]
USD 4,500.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Pharma & Healthcare [2]
Biotechnology [3]
Healthcare [4]
Therapeutic [5]
Description: 
鈥IMMUNE CHECKPOINT THERAPEUTICS 鈥 HOT TARGETS & PIPELINE ANALYSIS鈥 gives comprehensive insights on the various Immune Checkpoint modulators being developed for the treatment of various diseases. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins, Bi-specific Ab鈥檚, Antibody drug conjugates, Cell therapy, Peptides, Oncolytic viruses and Vaccines. The report also covers hot targets in research for Checkpoint modulators.
听
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space. The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents.
听
In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response. However, as a part of the natural fail鈥搒afe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers (鈥渋mmune checkpoint receptors鈥) found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound. Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease.
Table Of Contents: 

REPORT DESCRIPTION

INTRODUCTION

鈥 Emerging role of immunotherapy
鈥 Immune checkpoints

HOT TARGETS

鈥 Immune checkpoints-Types
鈥 Stimulatory checkpoint pathways
鈥 Inhibitory checkpoint pathways
鈥 Targets 鈥 Immune checkpoints
鈥 Other immune checkpoint targets
鈥 Top companies 听based on revenue
鈥 Top companies 听based on Pipeline

MARKET SIZING & DEALS ANALYSIS

鈥 麻豆原创 dynamics
鈥 麻豆原创 sizing
鈥 Immune checkpoint Deals

PIPELINE ANALYSIS

鈥 Development stage
鈥 Leading players
鈥 Target analysis
鈥 Modalities
鈥 Therapeutic Segmentation
鈥ncology immune checkpoint pipeline by indication

SMALL MOLECULES

鈥 Pipeline
鈥 Competitive landscape

MONOCLONAL ANTIBODIES

鈥 Pipeline
鈥 Competitive landscape

RECOMBINANT FUSION PROTEINS听

鈥 Pipeline
鈥 Competitive landscape

BISPECIFIC ANTIBODIES

鈥 Pipeline
鈥 Competitive landscape

NTIBODY DRUG CONJUGATES (ADC鈥檚)

鈥 Pipeline
鈥 Competitive landscape

OTHERS

鈥 Pipeline
鈥 Competitive landscape

MAJOR PLAYERS

鈥 Company Profiles
鈥 Overview, Pipeline & Deals
Companies Mentioned: 
  1. AGENUS INC
  2. APOGENIX AG
  3. ASTRAZENECA
  4. BAXALTA
  5. BRISTOL-MYERS SQUIBB CO.
  6. COMPUGEN INC.
  7. INCYTE CORPORATION
  8. INNATE PHARMA S.A.
  9. ROCHE
  10. TESARO
License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/iq4i/immune-checkpoint-therapeutics-hot-targets-pipeline-analysis

Links
[1] /countries/global[2] /pharma-healthcare[3] /biotechnology[4] /healthcare[5] /therapeutic